PDGFRA and gastrointestinal stromal tumor: KIT/PDGFRA-selective targeted inhibitors have been developed and applied to the treatment of gastrointestinal stromal tumors (GISTs).1,2 Imatinib emerged as the first-line treatment for GISTs, except for those with PDGFRA D842V mutation, for which Avapritinib was the first-line treatment.